8-K: Ventyx Biosciences Acquired by Eli Lilly for $1.2 Billion

Ventyx Biosciences, Inc. has completed its merger with Eli Lilly and Company, becoming a wholly-owned subsidiary.

Summary

• Ventyx Biosciences, Inc. completed its merger with Eli Lilly and Company's subsidiary, RYLS Merger Corporation, on March 4, 2026.
• Each share of Ventyx's common stock was converted into the right to receive $14.00 in cash.
• Each share of Ventyx's preferred stock was converted into the right to receive $1,400.00 in cash.
• Outstanding company stock options were cancelled in exchange for cash equal to the product of the number of shares multiplied by the excess of $14.00 over the exercise price, if positive.
• Outstanding restricted stock units (RSUs) were cancelled in exchange for cash equal to the product of the number of shares multiplied by $14.00.
• The aggregate consideration paid to stockholders and other equity holders in connection with the merger is approximately $1.2 billion.
• Ventyx's 2021 Employee Stock Purchase Plan, 2019 Equity Incentive Plan, and 2021 Equity Incentive Plan were terminated.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive event for Ventyx Biosciences shareholders, as the completion of the merger at a fixed cash price of $1.2 billion provides a clear and substantial return on investment, eliminating market volatility and uncertainty.

Positives

• Shareholders received a cash payment of $14.00 per common share and $1,400.00 per preferred share, representing a definitive value for their holdings.
• Equity award holders received cash for their vested and unvested options and RSUs, providing liquidity and value realization.

Negatives

• Ventyx Biosciences' common stock was delisted from the Nasdaq Global Select Market, removing public trading access for investors.
• Existing shareholders ceased to have any rights as stockholders of the company, other than the right to receive the merger consideration.

Risks

• Former public shareholders no longer have exposure to Ventyx Biosciences' future growth or performance as an independent entity.
• The delisting removes liquidity for any remaining shares not yet converted to cash.

Future Outlook

Ventyx Biosciences, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company, and its independent future outlook is integrated into the parent company's strategic plans. The filing does not provide specific forward-looking statements for the acquired entity.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly aligns with the broader pharmaceutical industry trend of larger companies acquiring innovative biotech firms to bolster their pipelines and expand therapeutic areas. Such mergers often provide a clear exit strategy and significant returns for early investors in the acquired biotech, while offering the acquirer access to promising drug candidates and research capabilities.

Comparison to Industry Standards

• The acquisition of Ventyx Biosciences for approximately $1.2 billion reflects a significant valuation for a biotech company, consistent with the high premiums often observed in the pharmaceutical sector for companies with promising clinical assets or platforms.
• While specific comparable companies or projects are not detailed in the filing, the cash-per-share consideration provides a clear benchmark for Ventyx shareholders against their initial investment and market expectations prior to the merger announcement.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, concluding their investment in Ventyx Biosciences.
• Employees (equity holders): Received cash for their stock options and RSUs, providing a liquidity event.
• Customers/Suppliers: No direct impact mentioned in the filing, but operations will now be under Eli Lilly's umbrella.
• Creditors: No specific impact mentioned, but the company's financial backing is now Eli Lilly.

Next Steps

• Nasdaq will suspend trading of Ventyx Biosciences common stock, withdraw it from listing, and file Form 25 with the SEC.
• Ventyx Biosciences intends to file Form 15 with the SEC to terminate registration of its common stock under the Exchange Act and suspend its reporting obligations.

Key Dates

Keywords

Merger, Acquisition, Eli Lilly, Ventyx Biosciences, Delisting, Biotechnology, Pharmaceuticals, Cash Consideration, Corporate Governance